Business Wire

WE-ARE-INNOVATION

9.4.2024 07:01:33 CEST | Business Wire | Press release

Share
Innovation Meets Regulation: International Webinar Explored Effective Anti-Smoking Strategies

We Are Innovation hosted the webinar “Innovation Meets Regulation: The 2024 Effective Anti-Smoking Policies Global Index.” This powerful talk embarked on the official start of the campaign dedicated to the launch of the anti-smoking index. The webinar, featuring Members of the European Parliament, regulatory experts, economists, and innovation experts, shed light on the regulatory frameworks regarding anti-smoking policies from the most prominent global authorities in the field.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240408705665/en/

Federico N. Fernández stated, “At We Are Innovation, we work on issues that require innovative approaches and solutions. One area we recognize as having significant potential for improvement is in innovative nicotine products. Our index encompasses a global population of 5.5 billion individuals, giving the ability to see the differences in global anti-smoking policies and windows for improvement.”

Eric Crampton added, “By showcasing the effectiveness of alternative products, the Index provides a new perspective on addressing smoking-related issues. Moving beyond punishing policies, we can advocate for better regulations that offer innovative solutions to combat smoking habits and promote healthier choices across the globe.”

Guy Bentley covered the situation in the US, “Safer e-cigarettes are seen as far more dangerous than regular cigarettes, even in comparison to the state of affairs 10 years ago which is a significant failure. Now we see the consequences of the informational blockage equal to the so-called ‘invisible graveyard’ — while the safer alternative can come to the market, the delay in the decision-making on the side of the officials that prevents, will lead to the deaths of people who could have been saved if the alternative was available.

MEP Johan Nissinen adds on Swedish policies, “With the new government, in Sweden we introduced higher taxes on cigarettes and lower on snus. The new regulations will come in November of this year. Currently, in Sweden the number of smokers is 5,6 percent while in the EU the average rate is ~23 percent.”

Matt Ridley gave a thought on the UK regulations, “I do not smoke myself, nor I vape, but as a person who is interested in innovations, I see the superior innovative product replacing inferior one which comes together with saving a large amount of lives. When considering the risks associated with vaping, it becomes evident that it offers a significantly smaller risk in terms of carcinogens and is a safer alternative. Government’s policy on vaping has led to the opening of the vaping industry in Britain, catering to a large market of individuals seeking to quit smoking.”

“Innovative nicotine products should be accompanied by smart regulations that balance out public health interests and individual freedoms. By embracing a forward-thinking approach, we can effectively address the problem of smoking,” summed up Tetiana Rak.

Learn more about the 2024 Effective Anti-Smoking Policies Global Index at https://antismoking.global/. The recording of the webinar is available at https://youtu.be/qAYcPAq6rh4.

ABOUT WE ARE INNOVATION

We Are Innovation is a dynamic network of individuals and institutions who fervently believe in the power of innovation to drive progress and solve the world’s most pressing problems. With a global presence encompassing over 40 think tanks, foundations, and NGOs, We Are Innovation represents the diverse voices of a global civil society committed to advancing human creativity, embracing new technologies, and promoting innovative solutions. Through our collaborative approach and cutting-edge expertise, we are spearheading transformative change on a global scale. To learn more about our work, visit us at https://weareinnovation.global/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408705665/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye